Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gynecologic 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Head and Neck Neoplasms 1Glioma 1Advanced Malignancies 1Advanced Cancer 1

Interventions

Temozolomide 41Radiotherapy 15Magnetic Resonance Spectroscopy 12Surgical Procedures, Operative 10Bevacizumab 10Irinotecan 9Radiation 8Nivolumab 7Carmustine 7Specimen Handling 6Radiosurgery 6Carboplatin 6ribociclib 5O(6)-benzylguanine 5Imiquimod 5IL13-PE38 5Flucytosine 5Filgrastim 5Erlotinib Hydrochloride 5Cyclophosphamide 5Aminolevulinic Acid 5vandetanib 4sargramostim 4Topotecan 4Lomustine 4Imatinib Mesylate 4Etoposide 4Craniotomy 4vocimagene amiretrorepvec 3temsirolimus 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Glioma × cabiralizumab × Clear all
NCT02526017 2022-03-09

FPA008-003

Five Prime Therapeutics, Inc.

Phase 1 Completed
313 enrolled 30 charts
CNSGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioma, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡